Examorelin
Also known as: EP-001, EP-23905, Examorelin acetate, GHRH‑examorelin, Hexarelin, MF-6003
Source Examorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Synthetic GHRH analog that potently increases endogenous GH release; investigated for GH deficiency, muscle wasting, and anti‑aging applications.
Mechanism of Action
Agonist at the GHRH receptor on pituitary somatotrophs, stimulating secretion of growth hormone
Routes of Administration
Goals & Uses
- Increase GH secretionEndocrineModerate
- Treat adult GH deficiencyTherapeuticLow
- Cachexia / muscle wastingMetabolic / Body CompositionLow
- Cardiac protection / dysfunctionCardiovascularModerate
- Treatment of GH deficiencyEndocrine / TherapeuticModerate
- IGF-1 elevationMetabolic / HormonalModerate
- Growth hormone stimulationEndocrine / HormonalHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Diabetic retinopathyOphthalmologyModerate
- Acromegaly or gigantismEndocrineHigh
Adverse Effects
- HypoglycemiaMetabolicRareAbnormally low blood glucose
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Injection site reactionsLocalCommon
- Carpal tunnel syndromeMusculoskeletalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Tachyphylaxis / GH desensitizationPharmacodynamicCommon
- Water retention / edemaFluid BalanceUncommon
- FlushingVascularCommonWarmth and redness of the skin
- Cortisol and prolactin elevationEndocrineCommon
Drug Interactions
- GlucocorticoidsModerate
- Somatostatin analogs (e.g., octreotide)High
- Insulin / antidiabetic agentsModerate
- CorticosteroidsModerate
- Somatostatin analogues (e.g., octreotide)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Athletes subject to WADA regulationsRegulatory / SportsAbsolute
- Patients with diabetes mellitusMetabolicRelative
- Elderly patientsAgeRelative
- Children with GH deficiencyPediatricRelative
Regulatory Status
- European UnionInvestigationalUnder clinical evaluation; not authorized.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalNot licensed; available only in research settings.
Not approved for clinical use in any major jurisdiction; studied in Phase I/II trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Examorelin?
Synthetic GHRH analog that potently increases endogenous GH release; investigated for GH deficiency, muscle wasting, and anti‑aging applications.
What is Examorelin used for?
Examorelin is educationally associated with: Increase GH secretion, Treat adult GH deficiency, Cachexia / muscle wasting, Cardiac protection / dysfunction, Treatment of GH deficiency, IGF-1 elevation, Growth hormone stimulation. Educational only — not medical advice.
How is Examorelin administered?
Recorded routes of administration: Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of Examorelin?
Reported adverse effects include: Hypoglycemia, Hyperglycemia, Injection site reactions, Carpal tunnel syndrome, Headache, Tachyphylaxis / GH desensitization, Water retention / edema, Flushing, Cortisol and prolactin elevation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Examorelin?
Recorded contraindications: Active malignancy, Pregnancy, Diabetic retinopathy, Acromegaly or gigantism. Consult a qualified clinician before use.